Natera, Inc., a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical trials using Natera’s SignateraTM molecular residual disease (MRD) assay as a biomarker to assess treatment response. View PDF
About Aurelie Kowalski
This author has yet to write their bio.Meanwhile lets just say that we are proud Aurelie Kowalski contributed a whooping 3 entries.
Entries by Aurelie Kowalski
SITC 2019 November 6 – 10, 2019 / Washington / USA Madiha Derouazi attending
Swiss Biotech Day 2019 May 7, 2019 / Basel / Switzerland Laurence de Schoulepnikoff attending